Articles

Compugen seeks to usher in ‘new era’ in oncology

Company identifies binding partner for CGEN-15029 and moves closer to IND filing
Written byLori Lesko
| 3 min read

TEL AVIV, Israel—Seeking to breach significant barriers and make up for lost time, Compugen Ltd., a leading predictive drug discovery company, has presented landmark findings from studies of CGEN-15029, the lead internal program in the company’s immuno-oncology therapeutics pipeline and treatment for metastatic melanoma—opening the door to what it deems a “new era of oncological inquiry and medicine.”

Compugen unveiled its promising results Feb. 29 before the New York Academy of Sciences’ Cancer Immunotherapy Conference, in a presenation entitled “Emerging Approaches to Cancer Immunotherapy.”

Compugen reported that initial validation studies show that expression of CGEN-15029 in T cells inhibits their activation by melanoma cells, consistent with an immune-suppressive role of the target in the tumor microenvironment. The target possesses signature immune-checkpoint receptor characteristics, including expression in relevant subsets of T cells and natural killer cells, with particularly high expression in lymphocytes that populate the tumor microenvironment (known as tumor infiltrating lymphocytes).

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.